Bone Biologics, Corp., a Los Angeles-based developer of a proprietary protein for use in bone regenerative medicine, completed a $5m funding round.
Hankey Investment Company, LP, of Los Angeles CA, made the investment.
The company intends to use the funds to begin the process of manufacturing Nell-1 in preparation for human clinical trials to validate the technology in regenerative medicine for bone.
Led by Michael Schuler, CEO, Bone Biologics is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or Nell-1) for use with patients undergoing spinal fusion.
Nell-1 has been developed by the company in partnership with University of California, Los Angeles (UCLA) and the Musculoskeletal Transplant Foundation (MTF) as a more specific alternative to other bone growth factors used in health care today.